We found that CD19 expression levels were significantly decreased in some samples (DLBCL2, 1/3 samples; FL1 and FL3, 2/4 samples; tFL1, 1/2 samples), MS4A1 in DLBCL1 and DLBCL3 (2/3 samples), CD22 in some DLBCL samples (DLBCL1 and DLBCL3, 2/3 samples) and FL1 (1/4 samples). The gene discussed is CD22; the disease is diffuse large B-cell lymphoma.